NCT01813084

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729

A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Respivert Ltd · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

RV1729 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of RV1729.

Conditions

• Asthma
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	RV1729 single dose	Safety and tolerability of single escalating doses
DRUG	RV1729 matching placebo single dose	Safety and tolerability of single escalating doses
DRUG	RV1729: 14 day repeat dose	Safety and tolerability of repeat escalating doses
DRUG	RV1729 matching placebo: 14 day repeat dose	Safety and tolerability of repeat escalating doses

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2013-03-18
• Last updated: 2014-04-24

Locations

2 sites across 1 country: United Kingdom